期刊文献+

α-synuclein致病机制和转基因帕金森疾病模型研究进展 被引量:4

The Advances in α-synuclein Toxic Mechanisms and Transgenic Models of Parkinson Disease
下载PDF
导出
摘要 α-synuclein是一种位于突触前末梢的蛋白,是遗传性和散发性帕金森病的特征性包涵体———路易小体的主要成分。α-synuclein基因突变或者遗传改变可导致帕金森病。大量研究揭示α-synuclein参与了神经元的变性过程。本文对α-synuclein在帕金森疾病中的神经元毒性机制以及α-synuclein转基因帕金森病动物模型研究进展进行了综述。 α-synuclein, a presynaptic protein, was found to be the major component of the lewy bodies in inherited and sporadic Parkinson's disease(PD), α-synuclein point mutations or genetic alteration can cause Parkinson' s disease ( PD). It is thought to be involved in the processes of neurodegeneration. This paper reviewed the toxic mechanisms of α- synuclein in Parkinson disease and α- synuclein transgenic animal models.
作者 张丽 张连峰
出处 《中国比较医学杂志》 CAS 2012年第11期63-67,共5页 Chinese Journal of Comparative Medicine
基金 国家科技支撑计划课题(2012BA139B02) 国家"重大新药创制"科技重大专项课题(2011ZX09307-302)
关键词 Α-突触核蛋白 帕金森 疾病模型 转基因 α-synuclein Parkson disease Disease models Transgenic
  • 相关文献

参考文献29

  • 1Zhang ZX, Roman GC, Hong Z, et al. Parkinson' s disease in China: prevalence in Beijing, Xian, and Shanghai [ J]. The Lancet, 2005, 365(9459): 595-597.
  • 2Recchia A, Debtto P, Negro A, et al. Alpha-synuclein and Parkinson' s disease[J]. The FASEB Journal, 2004; 18 (6) : 617 -626.
  • 3Spillantini MG, Schmidt ML, Lee VM, et al. alpha-synuclein in Lewy bodies[J].Nature, 1997, 388 (6645) : 839 -840.
  • 4Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegeneratlve disorders[J]. Science, 2000, 287(5456) :1265 - 1289.
  • 5Caughey, B. ,Lansbury, P. T. Protofibdls, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders[ J]. Annu. Rev. Neurosci, 2003, 26 : 267 - 298.
  • 6Wright, J. A. , Wang, X. , Brown, D. R. Unique eopperinduced oligomers mediate alpha-synuelein toxicity [ J]. FASEB J., 2009, 23 (8) : 2384 - 2393.
  • 7Zakharov SD, HuUeman JD, Dutseva EA, et al. Helical alpha synuclein forms highly conductive ion channels [ J ]. Biochemistry, 2007, 46 : 14369 - 14379.
  • 8Waxman EA, Giasson BI. Molecular Mechanisms of ct - Synuclein Neurodegeneration[ J]. Bioehim Biophys Aeta, 2009, 1792(7) : 616 -624.
  • 9Gosavi N, Lee H J, Lee JS, et aL Golgi fragmentation occurs in the ceils with prefibrillar alphasynuclein aggregates and precedes the formation of fibrillar inclusion [ J]. J Biol Chem, 2002, 277 : 48984 - 48992.
  • 10Fan J, Hu Z, Zeng L, et al. Golgi apparatus and neurodegenerative diseases[ J]. Int J Dev Neurosei, 2008, 26 (6) : 523 -34.

二级参考文献10

  • 1萨姆布鲁克J 拉塞尔DW 黄培堂译.分子克隆实验指南(第3版)[M].北京:科学出版社,2002..
  • 2Kruger R,Kulm W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinsen' s disease [ J ]. Nat Genet, 1998,18:106- 108.
  • 3Ulmer T S, Bax A. Comparison of structureand dynamics ofmiceilebound human alpha-synuclein and Parkinson disease variants [J]. J Biol Chem,2005,280(52) :43179 - 43187.
  • 4Lee JM, Yah P,Michael KL, et al. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death[ J ]. J Neurosci ,2006,26( 1 ) :41 - 50.
  • 5Van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein [ J ]. J Neurosci, 2000,20 (16) :6021 - 6029.
  • 6Gispert S,Del Turco D,Garrett L,et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation[ J ]. Mol Cell Neurosci, 2003,24 (2) : 419 - 429.
  • 7Poon HF, Frasier M, Shreve N, et al. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenlc mice-a model of familial Parkinson' s disease [J]. Neurobiol Dis,2005,18(3) :492 - 498.
  • 8Schober A. Classic toxin-induced animal models of Parkinson' s disease:6-OHDA and MPTP[J]. Cell Tissue Res,2004,318( 1 ) :215 - 224.
  • 9Shirakashi Y, Kawamoto Y, Tomimoto H, et al. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice[J]. Acta Neuropathol (Berl) ,2006,112(6) :681 - 689.
  • 10Polymempoulos MH, Lavedan C, Lemy E, et al. Mutation in the alpha-synuclein gene identied in families with Parkinsen' s disease [J]. Science, 1997,276:2045 - 2047.

共引文献10

同被引文献61

  • 1吕荣祥.美多巴联合普拉克索治疗帕金森病的有效性及安全性研究[J].中国生化药物杂志,2014,34(3):153-155. 被引量:46
  • 2周长春,刘芝华,齐军.AP-1和肿瘤的关系研究进展[J].世界华人消化杂志,2006,14(1):1-5. 被引量:16
  • 3祝辉,杨日芳,李锦,姜玉,恽榴红.多巴胺D3受体选择性配体研究进展[J].解放军药学学报,2006,22(6):441-445. 被引量:2
  • 4Zhang ZX, Roman GC, Zhen H, et al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai [ J]. Lancet, 2005, 365(9459) : 595 -597.
  • 5Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders [ J ]. Science, 2000, 287 (5456) : 1265 - 1289.
  • 6Gomez-Isla T, Irizarry MC, Ami Mariash A, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synaclein A30P transgenic mice [J]. Neurobiol Aging, 2003, 24(2) : 245 -258.
  • 7Lin X, Pafisiadou L, Sgobio C, et al. Conditional expression of Parkinson's disease-related mutant alpha-synuclein in the midbrain dopaminergie neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1 [ J]. J Neurosci, 2012, 32 (27) : 9248 - 9264.
  • 8Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein [ J]. J Neurosci, 2000, 20(16) : 6021 -6029.
  • 9Kahle PJ, NeumannM, Ozmen L, et al. Subcellular localization of wild-type and Parkinsons disease-associated mutant a- synuclein in human and transgenic mouse brain [J]. J Neurosci, 2000, 20:6365 -6373.
  • 10Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of ct- synuclein in the nigrostriatal system [ J]. J Neurosci, 2002, 22 (7) : 2780 -2791.

引证文献4

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部